Non-animal soft gel capsule preparation, preparation method and use method thereof
By using non-animal gelling agents and water-soluble polymers in non-animal soft gel capsules, the problem of excessive dissolution and disintegration time in the prior art is solved, and complete dissolution or rupture in a short time is achieved. The effect increases the drug release speed and bioavailability.
Patent Information
- Application Number
- CN202080071265.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-09
- Filing Date
- 2020-10-08
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-10-08
AI Technical Summary
The dissolution and disintegration time of existing non-animal soft gel capsules is long and cannot meet the immediate release needs of drugs that require rapid relief such as analgesics and antihistamines.
Using a soft gel composition containing a non-animal source gelling agent and a water-soluble polymer, a 0.1N HCl at 37°C can be prepared completely in less than 30 minutes by adjusting the ratio and type of gelling agent and polymer. Dissolved or disintegrated soft gel capsule shell composition.
The soft gel capsules are completely dissolved or ruptured in a short period of time, which improves the drug release speed and bioavailability, and is suitable for drug forms that require rapid relief.
Smart Images

Figure BDA0003589288880000161 
Figure BDA0003589288880000171 
Figure BDA0003589288880000172
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 912,886, filed on October 9, 2019, which is incorporated herein by reference in its entirety. Field of the Invention
[0003] The present invention relates to non-animal soft gel capsule preparations. Also disclosed herein are methods for preparing such soft gel capsules and methods of using the same. Background Art
[0004] Encapsulating a solution or dispersion of a nutrient or pharmaceutical agent in a liquid carrier within a soft gel capsule provides numerous advantages over other dosage forms such as compressed, coated or uncoated solid tablets or bulk liquid formulations. Such encapsulated solutions or dispersions enable precise delivery of unit doses, which is particularly important when relatively small amounts of active ingredients must be administered. In addition, uniformity is more difficult to achieve in tableting processes where solids must be uniformly mixed and compressed, or when the total dose of active ingredient is incorporated into a bulk liquid carrier that must be measured before each oral administration.
[0005] In addition, soft gel capsules (most commonly soft gelatin capsules) provide a dosage form that is easier for patients to accept because the capsules are easy to swallow and do not need to be flavored to mask the unpleasant taste of the active agent. Compared to bulk liquids, soft gel capsules are also easier to transport by patients because only the required number of doses need to be taken out from the package.
[0006] The soft gel capsule of the drug further has the potential to improve the bioavailability of the medicament. Once the shell is broken, the active ingredient is rapidly released in liquid form. Unlike the case of compressed tablet compositions, complete disintegration of the capsule is not necessary for the active ingredient to become available for absorption. In addition, relatively insoluble active ingredients can be dispersed in liquid carriers to provide faster absorption.
[0007] Compared to soft gel capsules made from animal-derived gelatin, which take 5 to 15 minutes to rupture, current non-animal soft gels (e.g. and Softgel) dissolves in the dissolution medium in between 20 and 40 minutes. For immediate release products that require rapid relief (e.g., analgesics, antihistamines / allergy medications), such long dissolution times may cause problems for patients.
[0008] Therefore, there is a need for improved non-animal soft gel capsule formulations having shorter dissolution and / or disintegration times.
[0009] Brief description of the invention
[0010] According to various embodiments, soft gel compositions are disclosed herein, comprising a filler material encapsulated in a shell composition. The shell composition comprises a non-animal source gelling agent and a water-soluble polymer. In certain embodiments, when the shell composition is subjected to dissolution testing at 37°C in 900ml of 0.1N HCl and deionized water using a USP apparatus II with paddles at 75RPM, it completely dissolves in less than 30 minutes.
[0011] According to certain embodiments, a soft gel composition is disclosed, comprising a fill material encapsulated by a shell composition, the fill material comprising an active agent or a cosmetic agent, wherein the shell composition comprises: a non-animal source gelling agent comprising carrageenan, starch, or a combination thereof; and a water-soluble polymer comprising polyvinyl alcohol, pullulan gum, polylactic acid, polyvinyl alcohol-polyethylene glycol graft copolymer, high molecular weight polyethylene glycol, povidone, a surfactant, or a combination thereof.
[0012] Also disclosed herein are various embodiments of methods of making soft gel compositions comprising a non-animal derived gelling agent and a water soluble polymer.
[0013] According to further embodiments, disclosed herein are soft gel compositions comprising a fill material containing an active agent (or cosmetic agent) encapsulated by a shell composition comprising a non-animal derived gelling agent and a water-soluble polymer, and methods of making and processing the same.
[0014] According to yet further embodiments, disclosed herein are methods of treating a condition treatable by an active or cosmetic agent described herein by administering any of the soft gel compositions described herein to a subject in need thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The above and other features of the present disclosure, their nature and various advantages will become more apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings, in which:
[0016] Figure 1 The release profile of an active agent (e.g., ibuprofen) from a conventional non-gelatin capsule is illustrated compared to a soft gel capsule according to one embodiment. The release profile also illustrates the dissolution profile of a shell composition of a conventional non-gelatin capsule compared to a soft gel shell composition according to one embodiment. DETAILED DESCRIPTION OF THE INVENTION
[0018] Various embodiments of soft gel compositions (e.g., soft gel capsule film compositions encapsulating fill materials), methods of preparation, and methods of use thereof are described herein. It should be understood that the present invention is not limited to the details of the construction or process steps set forth in the following description. The present invention can have other embodiments and can be implemented or carried out in a variety of ways.
[0019] References throughout the specification to "one embodiment," "certain embodiments," "one or more embodiments," or "an embodiment" mean that the particular features, structures, materials, or characteristics described in connection with the embodiment are included in at least one embodiment of the invention. Thus, the appearance of phrases such as "in one or more embodiments," "certain embodiments," "in one embodiment," or "in an embodiment" in different places throughout the specification are not necessarily referring to the same embodiment of the invention. Furthermore, in one or more embodiments, the particular features, structures, materials, or characteristics may be combined in any suitable manner.
[0020] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a polymer" includes a single polymer as well as a mixture of two or more polymers.
[0021] As used herein, the term "about" in conjunction with a measured amount refers to the normal variation of the measured amount as would be expected by one of ordinary skill in the art when making the measurement and exercising a level of care commensurate with the objective of the measurement and the precision of the measuring equipment. In certain embodiments, the term "about" includes the stated value ±10%, such that "about 10" would include 9 to 11.
[0022] The term "at least about" used in conjunction with a measured amount refers to the normal variation of the measured amount and any amount above the measured amount as expected by a person of ordinary skill in the art when making the measurement and exercising a level of care that matches the goal of the measurement and the precision of the measuring equipment. In certain embodiments, the term "at least about" includes the stated value minus 10% and any higher number, so that "at least about 10" will include 9 and any value greater than 9. This term may also be expressed as "about 10 or greater". Similarly, the term "less than about" generally includes the stated value plus 10% and any lower number, so that "less than about 10" will include 11 and any value less than 11. This term may also be expressed as "about 10 or less".
[0023] The term "immediate release" means that a dosage form as disclosed herein (e.g., a soft gel capsule formulation) releases at least about 85% by weight, at least about 90% by weight, or at least about 95% by weight of the active agent (or cosmetic agent) encapsulated within the shell composition within about 30 minutes, or within about 45 minutes, or within about 60 minutes, as measured by in vivo dissolution at 37°C in 900 ml of 0.1N HCl (optionally with pepsin) using USP Apparatus II at about 50 RPM to about 250 RPM.
[0024] The term "controlled release" refers to a dosage form as disclosed herein (eg, a soft gel capsule formulation) that releases the active agent (or cosmetic agent) encapsulated within the shell composition over a period of time, for example to provide a once-daily or twice-daily dosage form.
[0025] The term "soft gel" as used herein does not imply that gelatin is necessarily a part of the shell composition (or film composition) and / or the filling material (or filling composition). In certain embodiments, the shell composition (or film composition) may include gelatin, while in other embodiments, the shell composition may not contain gelatin. Similarly, in certain embodiments, the filling material (or filling composition) may include gelatin, while in other embodiments, the filling material may not contain gelatin. Throughout the specification, the term "soft gel" may be used interchangeably with the term "soft shell".
[0026] Throughout the specification, the term "shell composition" is used interchangeably with the terms "film composition," "shell" and "film." These terms refer to the outer portion of a soft gel composition (e.g., these terms refer to the shell of a soft gel capsule encapsulating a fill material).
[0027] Throughout the specification, the term "fill material" is used interchangeably with the terms "fill composition" and "fill." These terms refer to the inner portion of the soft gel composition encapsulated by the shell composition (eg, the inner portion of a soft gel capsule).
[0028] Throughout the specification, the term "soft gel composition" can be used interchangeably with the term "soft gel formulation" and "dosage form". In certain embodiments, the term "soft gel composition" or the term "soft gel formulation" can be used interchangeably with the term "soft gel capsule composition" or the term "soft gel capsule formulation", respectively.
[0029] Unless otherwise indicated, all parts and percentages are by weight. If not otherwise indicated, the weight percentages (wt%) are based on the entire composition without any volatiles, ie, based on dry solid content.
[0030] Unless otherwise indicated herein, recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context.
[0031] The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to illustrate certain materials and methods and does not limit the scope. No language in the specification should be construed as indicating any non-claimed element is essential to the practice of the disclosed materials and methods.
[0032] Although the disclosure herein refers to specific embodiments, it should be understood that these embodiments are merely illustrative of the principles and applications of the present invention. Various modifications and variations may be made to the compositions and methods without departing from the spirit and scope of the present invention, which will be apparent to those skilled in the art. Therefore, it is intended that the present invention include modifications and variations within the scope of the appended claims and their equivalents.
[0033] Soft gel capsule preparation
[0034] Disclosed herein are soft gel capsule shell compositions comprising a non-animal source gelling agent and a water-soluble polymer. In certain embodiments, when the shell composition is subjected to dissolution at 37°C in 900ml 0.1N HCl and deionized water using a USP apparatus II with paddles at 50-250RPM (e.g., 75RPM), the shell composition is completely dissolved in less than 30 minutes. In certain embodiments, the soft gel capsule shell composition is dissolved in less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, or less than 5 minutes.
[0035] In certain embodiments of the soft gel capsule shell composition, the non-animal source gelling agent comprises carrageenan and starch. The weight ratio of carrageenan to starch in the soft gel capsule shell composition can be, for example, about 1:1 to about 1:10, about 1:1 to about 1:8, about 1:1 to about 1:5, or about 1:2.5 to about 1:4.5. In certain embodiments, including a water-soluble polymer in the soft gel capsule shell composition helps to make the weight ratio of carrageenan to starch (e.g., with respect to dissolution, disintegration, elasticity, strength, etc.) less critical than if the soft gel capsule shell composition does not include the water-soluble polymer described herein.
[0036] Also disclosed in certain embodiments are soft gel capsule formulations comprising a fill material containing an active agent, wherein the fill material is encapsulated by a shell composition as disclosed herein. The fill material may include, for example, a hydrophilic material, a lipophilic material, an amphiphilic material, or a combination thereof and an optional surfactant. The fill material may be a solution, a suspension, a semisolid or a solid and may further include an active agent (e.g., an active pharmaceutical ingredient or a nutraceutical) or a cosmetic agent.
[0037] The shell composition as disclosed herein may also contain at least one of a buffer, a plasticizer, and water. The soft gel capsule formulation as described herein may be vegetarian and free of animal-derived materials such as gelatin. In certain embodiments, the shell composition may contain less than 10 wt%, less than 5 wt%, less than 1 wt%, or 0 wt% of an animal-derived gelling agent.
[0038] In certain embodiments, when the shell composition disclosed herein is subjected to dissolution at 37°C in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) using a USP Apparatus II with paddles at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM), the shell composition is completely dissolved in less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, or less than 5 minutes.
[0039] In certain embodiments, when the shell composition disclosed herein is subjected to dissolution at 37°C in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) using a USP apparatus II with paddles at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM), the shell composition is completely dissolved within any of about 5 minutes, about 8 minutes, about 10 minutes, about 12 minutes, or about 15 minutes to any of about 20 minutes, about 23 minutes, about 25 minutes, about 28 minutes, about 30 minutes, or about 35 minutes.
[0040] In certain embodiments, when the shell composition disclosed herein is subjected to dissolution at 37°C in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) using a USP Apparatus II with paddles at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM), the shell composition begins to dissolve in less than 15 minutes, less than 10 minutes, less than 9 minutes, less than 8 minutes, or less than 7 minutes.
[0041] In certain embodiments, when the shell composition disclosed herein is subjected to dissolution at 37°C in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) using a USP apparatus II with paddles at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM), the shell composition begins to dissolve within any of about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or about 5 minutes to any of about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 15 minutes.
[0042] In certain embodiments, when a soft gel composition (e.g., a soft gel capsule) comprising a fill material encapsulated with a shell composition as disclosed herein undergoes disintegration at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM) in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) at 37° C., the soft gel composition begins to rupture in less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, or less than 5 minutes.
[0043] In certain embodiments, when a soft gel composition (e.g., a soft gel capsule) comprising a fill material encapsulated with a shell composition as disclosed herein undergoes disintegration at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM) in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) at 37° C., the soft gel composition begins to rupture within any of about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or about 7 minutes to any of about 8 minutes, about 9 minutes, about 10 minutes, about 15 minutes, or about 20 minutes.
[0044] In certain embodiments, when a soft gel composition (e.g., a soft gel capsule) comprising a fill material encapsulated with a shell composition disclosed herein undergoes disintegration at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM) in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) at 37° C., the soft gel composition is completely dissolved in less than 45 minutes, less than 40 minutes, less than 35 minutes, less than 30 minutes, or less than 25 minutes.
[0045] In certain embodiments, when a soft gel composition (e.g., a soft gel capsule) comprising a fill material encapsulated with a shell composition disclosed herein undergoes disintegration at about 50 RPM to about 250 RPM (e.g., about 50 RPM, or at about 75 RPM, or at about 100 RPM, or at about 150 RPM, or at about 200 RPM, or at about 250 RPM) in 900 ml of 0.1 N HCl with deionized water (optionally with pepsin) at 37° C., the soft gel composition is completely dissolved within any one of about 15 minutes, about 18 minutes, about 20 minutes, about 22 minutes, about 25 minutes to any one of about 30 minutes, about 35 minutes, about 40 minutes, or about 45 minutes.
[0046] It should be understood that the dissolution and / or disintegration time of the shell composition can be independent of the dissolution and / or disintegration time of the filling material. The release curve of the active agent from the dosage form can depend on the shell composition and the filling composition. The dissolution and / or disintegration time of the shell composition can at least partially indicate the release characteristics of the active agent from the dosage form. According to the embodiments described herein, the dosage form can be formulated as an immediate release dosage form (e.g., by preparing an immediate release shell composition with an immediate release filling material) and a controlled release dosage form (e.g., by preparing an immediate release shell composition with a controlled release filling material).
[0047] According to certain embodiments, the water-soluble polymer may include, for example, polyvinyl alcohol (PVA), pullulan, polylactic acid, polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG copolymer), high molecular weight polyethylene glycol, povidone, surfactant (e.g., sodium lauryl sulfate) or a combination thereof. In one embodiment, the water-soluble polymer is PVA. In one embodiment, the water-soluble polymer is PVA-PEG copolymer. In one embodiment, the water-soluble polymer is pullulan. The high molecular weight polyethylene glycol may be a polyethylene glycol having a number average molecular weight in the range of about 600Da to about 2,000,000Da and any number average molecular weight therein (e.g., PEG 600, PEG 800, PEG 1000, PEG 1500, PEG 3350, PEG 4000, PEG 6000, PEG8000, etc.). In certain embodiments, the amount of water-soluble polymer in the shell composition is, for example, from about 0.5 wt % to about 10 wt %, from about 0.5 wt % to about 12 wt %, from about 1 wt % to about 15 wt %, from about 1 wt % to about 20 wt %, from about 2 wt % to about 22 wt %, from about 2 wt % to about 7 wt %, from about 0.5 wt % to about 8 wt %, from about 3 wt % to about 9 wt %, from about 2.5 wt % to about 30 wt %, from about 10 wt % to about 50 wt %, or from about 20 wt % to about 40 wt %, or from about 15 wt % to about 30 wt %, or about 15 wt %, or about 18 wt %, or about 20 wt %, or about 22 wt %, or about 25 wt %, or about 28 wt %, or about 30 wt %, or any sub-range or single concentration value therein, wherein all wt % are based on the total weight of the shell composition.
[0048] According to an embodiment, the non-animal gelling agent may include, for example, carrageenan, starch, pregelatinized starch, xanthan gum, agar, pectin, alginate, sugar, sugar-source alcohol, monosaccharide, disaccharide, oligosaccharide, cellulose derivative, cellulose polymer, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, microcrystalline cellulose, attapulgite, bentonite, dextrin, alginate, kaolin, lecithin, magnesium aluminum silicate, carbomer, carbopol, silicon dioxide, curdlan, furcellaran, albumin (e.g., egg or lactic acid source), soy protein, chitosan, guaic gum, tamarind seed polysaccharide, glucomannan, chitin, pluran, cyclodextrin, or a combination thereof.
[0049] The carrageenan may be at least one of iota carrageenan, kappa carrageenan, and lambda carrageenan.
[0050] The starch may be modified starch or natural starch, sweet potato starch, potato starch, corn starch, tapioca starch, pea starch, hydroxypropylated starch, hydroxyalkylated starch, acid-treated starch, dextrin, high-amylose non-modified corn starch, modified waxy corn starch, non-granular starch, modified high-amylose corn starch, pregelatinized rice flour, and combinations thereof. As used herein and in the claims, the term "modified starch" includes, for example, hydroxypropylated starch, acid-thinned starch, and the like. In general, modified starch is a product prepared by chemically treating starch, such as acid-treated starch, enzyme-treated starch, oxidized starch, cross-linked starch, and other starch derivatives. Preferably, the modified starch is derivatized, wherein the side chains are modified with hydrophilic or hydrophobic groups to thereby form a more complex structure with strong interactions between the side chains.
[0051] In certain embodiments, the amount of non-animal gelling agent in the shell composition is: for example, from about 2% to about 20% by weight, from about 2% to about 15% by weight, from about 2% to about 40% by weight, from about 10% to about 80% by weight, or from about 15% to about 75% by weight, or from about 20% to about 70% by weight, or from about 25% to about 60% by weight, or from about 25% to about 45% by weight, or from about 20% to about 35% by weight, or from about 30% to about 40% by weight, or from about 32% by weight, or from about 35% by weight, or from about 38% by weight, or any sub-range or single concentration value therein, wherein all % by weight are based on the total weight of the shell composition. In one embodiment, the non-animal gelling agent includes carrageenan and does not include starch (or modified starch). In one embodiment, the soft gel shell composition is substantially free of or free of starch (or modified starch).
[0052] In certain embodiments, the weight ratio of the water-soluble polymer (e.g., PVA, PVA-PEG copolymer, pullulan, or a combination thereof) to the non-animal gelling agent (e.g., carrageenan, starch, or a combination thereof) may be in the range of about 20: 1 to about 1:20, about 15: 1 to about 1:15, about 10: 1 to about 1:10, about 8: 1 to about 1:8, about 5: 1 to about 1:5, about 3: 1 to about 1:3, or about 2: 1 to about 1:2, or about 1: 1. Without being construed as limiting, it is believed that the weight ratio of the water-soluble polymer to the non-animal gelling agent has an impact on the dissolution time of the soft gel shell compositions described herein.
[0053] According to an embodiment, the buffer comprises at least one of: disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium bicarbonate, sodium citrate, disodium phosphate, calcium phosphate, dicalcium hydrogen phosphate, tricalcium phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate. In an embodiment, the buffer comprises disodium hydrogen phosphate. In an embodiment, the amount of the buffer in the shell composition is from about 0.01 wt % to about 5 wt %, or from about 0.05 wt % to about 4 wt %, or from about 0.1 wt % to about 3 wt %, or from about 0.5 wt % to about 3 wt %, or about 1.0 wt %, or any sub-range or single concentration value therein, wherein all wt % are based on the total weight of the shell composition.
[0054] According to various embodiments, the plasticizer may include, for example, glycerol, sorbitol, sorbitol and sorbitan solution, triacetin, polysorbate, propylene glycol, sodium lauryl sulfate (SLS), sugar alcohol (e.g., maltitol), or a combination thereof. In certain embodiments, the plasticizer is glycerol. In one embodiment, the plasticizer is sorbitol. In one embodiment, the plasticizer is SLS. In an embodiment, the amount of the plasticizer in the shell composition is: about 0.5 wt % to about 40.0 wt %, 10 wt % to about 30.0 wt %, or about 12 wt % to about 28 wt %, or about 15 wt % to about 30 wt %, or about 18 wt % to about 23 wt %, or about 18 wt %, or about 20 wt %, or about 22 wt %, or about 25 wt %, or about 28 wt %, or about 30 wt %, or any sub-range or single concentration value therein, wherein all wt % are based on the total weight of the shell composition.
[0055] In certain embodiments, the soft gel capsule shell composition contains water. Water can be present in the shell composition in the following amount: about 30% by weight to about 60% by weight, or about 35% by weight to about 55% by weight, or about 40% by weight to about 50% by weight, or about 42% by weight, or about 43% by weight, or about 44% by weight, or about 45% by weight, or about 45.5% by weight, or about 46% by weight, or about 47% by weight, or about 48% by weight, or any sub-range or single concentration value therein, wherein all weight % are based on the total weight of the shell composition. According to certain embodiments, the weight ratio of water to non-animal gelling agent in the shell composition is about 1:5 to about 5:1, or about 1:4 to about 4:1, or about 1:3 to about 3:1, or about 1:1, or about 2:1, or about 3:1, or about 4:1, or about 5:1.
[0056] In certain embodiments, as measured by a texture analyzer according to the detailed description in the examples, the soft gel shell compositions described herein have a film strength greater than about 5.0 kg, greater than about 5.2 kg, or greater than about 5.4 kg. In certain embodiments, the film strength of the soft gel shell compositions described herein is in the range of about 3.5 kg, about 4.0 kg, about 4.5 kg, about 5.0 kg, or about 5.5 kg, to about 6.0 kg, about 6.5 kg, about 7.0 kg, about 7.5 kg, about 8.0 kg, about 8.5 kg, about 9.0 kg, about 9.5 kg, about 10.0 kg, about 10.5 kg, about 11.0 kg, about 11.5 kg, or about 12.0 kg, or any single value or subrange therein. In certain embodiments, the film strength of the soft gel shell compositions described herein ranges from about 3.5 kg to about 12.0 kg, from about 5.0 kg to about 12.0 kg, from about 5.2 kg to about 10.0 kg, or from about 5.0 kg to about 7.0 kg.
[0057] In certain embodiments, as measured by the texture analyzer described in detail in the embodiment, the soft gel shell composition described herein has an elasticity greater than about 7.7mm, greater than about 8.0mm or greater than about 8.2mm. In certain embodiments, the elastic range of the soft gel shell composition described herein is about 6mm, about 6.5mm, about 7.0mm, about 7.5mm, about 8.0mm or about 8.5mm, any one of about 9.0mm, about 9.5mm, about 10.0mm, about 10.5mm, about 11.0mm, about 11.5mm or about 12.0mm, or any single value or sub-range therein. In certain embodiments, the elasticity of the soft gel shell composition described herein is about 6.0mm to about 12.0mm, about 7.0mm to about 10.0mm, about 8.0mm to about 12.0mm or about 8.0mm to about 10.0mm.
[0058] In certain embodiments, the soft gel shell compositions described herein are sufficiently elastic to allow for capsule formation, while also being sufficiently strong to withstand handling in an encapsulation machine (e.g., a rotary mold), and provide good sealing properties at temperatures below the melting point of the soft gel shell composition, all without compromising the dissolution or disintegration properties of the soft gel shell composition and the capsule.
[0059] The soft gel capsule formulation as disclosed herein may further comprise a filling material. The filling material may contain at least one of rapeseed oil, medium chain triglyceride oil, polyethylene glycol, and a combination thereof. Lipophilic and / or hydrophilic and / or alcohol filling materials may also be encapsulated with the soft gel capsule filling materials described herein.
[0060] Active Agent
[0061] Any pharmaceutically active ingredient may be used for the purpose of the present invention, including all water-soluble ingredients and those that are poorly soluble in water. Suitable pharmaceutical active ingredients include, but are not limited to, analgesics and anti-inflammatories, antacids, anthelmintics, antiarrhythmics, antibacterials, anticoagulants, antidepressants, antidiabetics, antidiarrheals, antiepileptics, antifungals, antigouts, antihypertensives, antimalarials, antimigraines, antimuscarinics, antineoplastics and immunosuppressants, antiprotozoals, antirheumatic agents, antithyroid agents, antivirals, anxiolytics, sedatives, hypnotics and neuroleptics, beta-blockers, cardiac inotropes, corticosteroids, cough suppressants, cytotoxic agents, decongestants, diuretics, enzymes, antiparkinsonian agents, gastrointestinal agents, histamine receptor antagonists, lipid-regulating agents, local anesthetics, neuromuscular agents, nitrates and antianginal agents, nutritional agents, opioid analgesics, oral vaccines, proteins, peptides and recombinant drugs, sex hormones and contraceptives, spermicides, stimulants, and combinations thereof.
[0062] In some embodiments, the active pharmaceutical ingredient can be selected from, but not limited to, dabigatran, dronedarone, ticagrelor, iloperidone, ivacaftor, midostaurin, acimadolin, beclomethasone, apremilast, sapacitabine, linsitinib, abiraterone, vitamin D analogs (e.g., calcifediol, calcitriol, paricalcitol, doxorcalciferol), COX-2 inhibitors (e.g., celecoxib, valdecoxib, rofecoxib), tacrolimus, testosterone, lubiprostone, pharmaceutically acceptable salts thereof, and combinations thereof.
[0063] In some embodiments, the lipid in the dosage form can be selected from, but not limited to, almond oil, argan oil, avocado oil, borage seed oil, canola oil, cashew oil, castor oil, hydrogenated castor oil, cocoa butter, coconut oil, rapeseed oil, corn oil, cottonseed oil, grapeseed oil, hazelnut oil, hemp oil, hydroxylated lecithin, lecithin, linseed oil, macadamia oil, mango butter, abaca oil, mongongo nut oil, olive oil, palm kernel oil, palm oil, peanut oil, pecan oil, perilla oil, pine nut oil, pistachio oil, poppy seed oil, pumpkin seed oil, rice bran oil, safflower oil, sesame oil, shea butter, soybean oil, sunflower seed oil, hydrogenated vegetable oil, walnut oil, and watermelon seed oil. Other oils and fats can include, but are not limited to, fish oil (omega-3), krill oil, animal or vegetable fats (e.g., in their hydrogenated forms), free fatty acids, and mono-, di-, and triglycerides containing C8-, C10-, C12-, C14-, C16-, C18-, C20-, and C22-fatty acids, and combinations thereof.
[0064] According to certain embodiments, the active agent may comprise a lipid-lowering agent, which includes, but is not limited to, statins (e.g., lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin), fibrates (e.g., clofibrate, ciprofibrate, bezafibrate, fenofibrate and gemfibrozil), niacin, bile acid sequestrants, ezetimibe, lomitapide, phytosterols, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, mixtures of any of the foregoing, and the like.
[0065] Suitable nutritional actives may include, but are not limited to, 5-hydroxytryptophan, acetyl-L-carnitine, alpha-lipoic acid, alpha-ketoglutarate, bee products, betaine hydrochloride, bovine cartilage, caffeine, cetyl myristate, charcoal, chitosan, choline, chondroitin sulfate, coenzyme Q10, collagen, colostrum, creatine, cyanocobalamin (vitamin B12), dimethylaminoethanol, fumaric acid, germanium sesquioxide, glandular products, glucosamine HCI, glucosamine sulfate, methyl hydroxybutyrate, immunoglobulins, lactic acid, L-carnitine, liver products, malic acid, anhydrous maltose, mannose (d-mannose), methylsulfonylmethane, phytosterols, picolinic acid, pyruvic acid, red yeast extract, S-adenosylmethionine, selenium yeast, shark cartilage, theobromine, vanadyl sulfate, and yeast.
[0066] Suitable nutritional supplement actives may include vitamins, minerals, fiber, fatty acids, amino acids, herbal supplements, or combinations thereof.
[0067] Suitable microbial active agents may include, but are not limited to, the following: ascorbic acid (vitamin C), B vitamins, biotin, fat-soluble vitamins, folic acid, hydroxycitric acid, inositol, ascorbic acid mineral salts, mixed tocopherols, niacin (vitamin B3), orotic acid, para-aminobenzoic acid, pantothenate, pantothenic acid (vitamin B5), pyridoxine hydrochloride (vitamin B6), riboflavin (vitamin B2), synthetic vitamins, thiamine (vitamin B1), tocotrienols, vitamin A, vitamin D, vitamin E, vitamin F, vitamin K, vitamin oils, and oil-soluble vitamins.
[0068] Suitable herbal supplement actives may include, but are not limited to, the following: arnica, bilberry, black cohosh, cat's claw, chamomile, echinacea, evening primrose oil, fenugreek, flaxseed, feverfew, garlic, ginger root, ginkgo biloba, ginseng, goldenrod, hawthorn, kava-kava, licorice, milk thistle, plantain, rauwolfia, senna, soy, St. John's wort, saw palmetto, turmeric, valerian.
[0069] Mineral actives may include, but are not limited to, the following: boron, calcium, chelated minerals, chlorides, chromium, coated minerals, cobalt, copper, dolomite, iodine, iron, magnesium, manganese, mineral premixes, mineral products, molybdenum, phosphorus, potassium, selenium, sodium, vanadium, malic acid, pyruvate, zinc and other minerals.
[0070] Examples of other possible active substances include, but are not limited to, antihistamines (e.g., ranitidine, dimenhydrinate, diphenhydramine, chlorpheniramine, and dexchlorpheniramine maleate), nonsteroidal anti-inflammatory drugs (e.g., aspirin, celecoxib, Cox-2 inhibitors, diclofenac, benoxaprofen, flurbiprofen, fenoprofen, flubufen, indoibuprofen, pirprofen, carprofen, oxaprozin, pranoprofen, moroprofen, trimeprofen, suprofen, aminoprofen, fluprofen, buclofen, indomethacin, sulindac, zomepirac, tiopine, zidometacin, acemetacin, fentiazolic, cyclanac, oxpinac, meclofenamic acid, Flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenamic acid, piroxicam, sudoxicam, isoxicam, aceclofenac, aloprin, azapropazone, benolate, bromfenac, carprofen, choline magnesium salicylate, diflunisal, etodolac, etoricoxib, faislamine, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, meloxicam, mefenamic acid, analgin, methyl salicylate, magnesium salicylate, nabumetone, naproxen, nimesulide, oxyphenbutazone, parecil The invention also includes but is not limited to: anticonvulsants (such as phenytoin, meprobamate and nitrazepam), vasodilators (such as nifedipine, papaverine, diltiazem and nicardipine), cough suppressants and expectorants (such as codeine phosphate), antiasthmatics (such as theophylline), antacids, anticonvulsants (such as atropine, scopolamine), antidiabetic drugs (such as pancreatic cannabinoids), and sedatives (such as tadalafil, tadalafil, sedatives). In some embodiments, the present invention relates to an agent that is suitable for use in the present invention and that is suitable for use in the present invention. The agent includes, but is not limited to, insulin, diuretics (e.g., edenic acid, bendrofluthiazide), antihypotensives (e.g., propranolol, clonidine), antihypertensives (e.g., clonidine, methyldopa), bronchodilators (e.g., salbutamol), steroids (e.g., hydrocortisone, triamcinolone, prednisone), antibiotics (e.g., tetracycline), antihemorrhoidal drugs, hypnotics, psychotropics, antidiarrheals, expectorants, sedatives, decongestants (e.g., pseudoephedrine), laxatives, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine) and cannabinoids, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof.
[0071] The active agent may also be a benzodiazepine benzodiazepines, barbiturates, stimulants, or mixtures thereof. Benzodiazepines Benzodiazepines Derivatives of the drug class that depress the central nervous system. Class includes, but is not limited to, alprazolam, bromazepam, diazepam , chlordiazepoxide, diazepam, estazolam, flurazepam, halazepam, ketazola, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, methylphenidate, and pharmaceutically acceptable salts, hydrates, solvates and mixtures thereof. Benzodiazepines that can be used as active agents Antagonists of the class include, but are not limited to, flumazenil, and pharmaceutically acceptable salts, hydrates, solvates, and mixtures thereof.
[0072] The term "barbiturates" refers to sedative hypnotic drugs derived from barbituric acid (2,4,6,-trioxohexahydropyrimidine). Barbiturates include, but are not limited to, amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, methylphenobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, and mixtures thereof. Barbiturate antagonists that can be used as active agents include, but are not limited to, amphetamine, and pharmaceutically acceptable salts, hydrates, solvates, and mixtures thereof.
[0073] The term "stimulant" includes, but is not limited to, amphetamines, such as dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate, and pharmaceutically acceptable salts, hydrates, and solvates thereof, and mixtures thereof. Stimulant antagonists that can be used as active agents include, but are not limited to, benzodiazepines. and pharmaceutically acceptable salts, hydrates, and solvates thereof, and mixtures thereof.
[0074] The soft gel capsule preparation according to the present disclosure includes various active agents and pharmaceutically acceptable salts thereof. Pharmaceutically acceptable salts include, but are not limited to, inorganic acid salts, such as hydrochlorides, hydrobromides, sulfates, phosphates, etc.; organic acid salts, such as formates, acetates, trifluoroacetates, maleates, tartrates, etc.; sulfonates, such as methanesulfonates, benzenesulfonates, p-toluenesulfonates, etc.; amino acid salts, such as arginine salts, aspartates, glutamates, etc.; and metal salts, such as sodium salts, potassium salts, cesium salts, etc.; alkaline earth metal salts, such as calcium salts, magnesium salts, etc.; organic amine salts, such as triethylamine salts, pyridine salts, methylpyridine salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N,N′-diphenylethylenediamine salts, etc.
[0075] Method for preparing soft gel capsule preparation
[0076] Disclosed herein are methods for preparing soft gel shell compositions and soft gel capsule formulations as disclosed herein. The method comprises combining a non-animal gelling agent, a water-soluble polymer, and at least one of an optional buffer, a plasticizer, or water to form a combination. The method further comprises heating the combination to form a melt. In an embodiment, the melt is a uniform melt. The method may further comprise extruding the melt to form a ribbon. Additionally, the method may comprise casting the ribbon on a drum and forming a soft capsule shell using a rotary mold encapsulation device. In an embodiment, the ribbon may have a thickness of, for example, about 0.001 inch to about 0.100 inch, about 0.001 inch to about 0.070 inch, about 0.001 inch to about 0.050 inch, or about 0.005 inch to about 0.030 inch, or about 0.010 inch to about 0.025 inch, or about 0.015 inch to about 0.021 inch, or about 0.017 inch, or about 0.018 inch, or about 0.019 inch, or about 0.020 inch, or about 0.021 inch, or about 0.022 inch. In certain embodiments, the netting may be formed by a combination. The netting may then be melted and reused to form the ribbon.
[0077] In one embodiment, the method may further include mixing a plasticizer with water (if both are present) to form a plasticizer solution. The method may further include mixing a synthetic polymer, a non-animal (natural) gelling agent, and a buffer (if present) with the plasticizer solution. In the same embodiment or in an alternative embodiment, the combination may further include mixing a plasticizer with a non-animal gelling agent to form a solution, mixing the solution with water to form a plasticizer solution, and mixing a water-soluble polymer and a buffer with a plasticizer solution (including a non-animal gelling agent). The combination may include introducing each of a water-soluble polymer, a non-animal gelling agent, a buffer, a plasticizer, and water into a low shear mixer. In an embodiment, the combination may last from about 1 minute to about 3 hours, or from about 5 minutes to about 2.5 hours, or from about 15 minutes to about 2.0 hours, or from about 20 minutes to about 1.5 hours, or from about 30 minutes to 1.0 hours, or from about 5 minutes to about 30 minutes. The combination may be performed at a temperature of about 45° C. to about 90° C., or about 50° C. to about 85° C., or about 55° C. to about 80° C., or about 60° C. to about 70° C., or about 55° C., or about 60° C., or about 65° C. The combination may further include increasing the temperature to about 95° C. to about 125° C., or about 100° C. to about 120° C., or about 105° C. to about 115° C., or about 95° C., or about 96° C., or about 97° C., or about 98° C., or about 99° C., or about 100° C.
[0078] According to certain embodiments, the method may further include transferring the combination to a receiving tank. The combination or material in the receiving tank may be transferred to a heating vessel to heat the material therein. In certain embodiments, the heating vessel may heat the combination to a temperature of about 80°C to about 115°C, or about 85°C to about 100°C, or about 88°C to about 95°C. According to certain embodiments, the method may include injecting a colorant into the combination.
[0079] The method may further include conveying the combination to an encapsulation device. In certain embodiments, the method may include encapsulating a fill material in a soft gel capsule fill material formed from any of the above combinations to form a plurality of soft gel capsule dosage forms. The method may further include drying a plurality of soft gel capsule dosage forms in a tumble dryer. Certain embodiments further include packaging a plurality of soft gel capsule dosage forms.
[0080] Treatment
[0081] Disclosed herein is a method for treating, preventing, minimizing or improving a condition in a subject in need that can be treated by an active agent included in the fill material of a soft gel capsule described herein. The method includes administering any of the soft gel capsules described herein to a subject in need, thereby treating, preventing, minimizing, improving or slowing down the condition after administering the soft gel capsule.
[0082] The terms "treatment of" and "treating" include the administration of an active agent to lessen the severity of a condition.
[0083] The terms "prevention of" or "preventing" include avoiding the onset of a disorder by prophylactic administration of an active agent.
[0084] The term "condition" may refer to those medical conditions that can be treated, prevented, minimized or improved by administering an effective amount of any of the active or cosmetic agents described herein. In certain embodiments, the term "condition" may refer to pain.
[0085] In certain embodiments, the soft gel capsules described herein (e.g., those comprising a non-animal-derived gelling agent, a water-soluble polymer, and at least one of a buffer, a plasticizer, and water) facilitate faster T compared to soft gel capsules that do not include one of the components described above (e.g., a water-soluble polymer). max .
[0086] T max It refers to the plasma concentration of active agent reaching C max time.
[0087] C max It refers to the maximum plasma concentration of the active agent.
[0088] As used herein, the term "effective amount" refers to the amount and / or ratio of an active or cosmetic agent required to produce the desired therapeutic or cosmetic result.
[0089] The term "subject" refers to a human or animal that has exhibited manifestations of a disorder (clinical or otherwise) indicating a need for treatment with any of the active agents described herein. Example
[0090] Specific embodiments of the present invention will now be described with reference to the following examples. It should be understood that these examples are disclosed only by way of illustration of the present invention and should not limit the scope of the present invention in any way.
[0091] Example 1
[0092] Comparison of soft gel capsule formulations for non-animal gelling agent capsule shell compositions without water soluble polymer (control) and with water soluble polymer. Dissolution was tested at 37°C in 900 ml of 0.1N HCl and deionized water using USP Apparatus II with paddles at 75 RPM. The shell compositions were tested as samples with a diameter of 1.0 inch (25.4 mm) and thicknesses of 0.7 mm and 1.4 mm.
[0093] Table 1
[0094]
[0095]
[0096] *Weight ratio relative to carrageenan
[0097] As can be seen in Table 1, the control non-animal gelling agent capsule shell composition without a water-soluble polymer had a dissolution time of 63.25 minutes and 71.05 minutes in water. In contrast, each non-animal gelling agent capsule shell composition with a water-soluble polymer (whether PVA itself, PVA and SLS or PVA-PEG copolymer) dissolved faster in water (less than 20 minutes) and in 0.1N HCl (less than 25 minutes).
[0098] Interestingly, faster dissolution was observed in the non-animal gellant capsule shell composition comprising PVA and SLS than in the non-animal gellant capsule shell composition comprising any of the other water-soluble polymers. The shell composition comprising PVA without SLS exhibited similar dissolution to the shell composition comprising PVA-PEG copolymer as the water-soluble polymer.
[0099] While not to be construed as limiting, it is believed that the type of water-soluble polymer as well as the weight ratio of carrageenan to a particular water-soluble polymer can affect the dissolution time of the shell composition.
[0100] Example 2
[0101] The solubility of various soft gel shell compositions was evaluated by incorporating natural or synthetic water-soluble polymers as shown in Table 2 below.
[0102] Table 2 - Soft gel shell composition
[0103]
[0104]
[0105] Soft gel shell compositions according to the above formulations (F-1 to F-6) were prepared. Formulations F-1 to F-4 were cast into films. Shell compositions F-1 to F-4 were dried to a moisture content of 6 wt%-15 wt% (based on the total weight of the shell composition). The film strength and elasticity of the dried shell compositions were evaluated using a texture analyzer. Table 3 summarizes the strength and elasticity of shell compositions prepared using various water-soluble polymers. The data were generated using dried shell compositions containing 6 wt%-15 wt% moisture based on the total weight of the soft gel shell composition.
[0106] The texture analyzer test conditions for measuring strength and elasticity are as follows: Soft gel films with compositions F-1 to F-4 are mounted on a platform. A quarter-inch spherical probe is advanced toward the soft gel film at 2 mm / sec until the probe penetrates the film. The force measured is the strength of the film. The distance measured is the elasticity of the film. The test is performed under ambient conditions.
[0107] Table 3 - Film strength and elasticity of soft gel shell compositions F-1 to F-4
[0108]
[0109] As can be seen in Table 3, the control non-animal gelling agent capsule shell composition without a water-soluble polymer has a strength of 4.9 kg and an elasticity of 7.5 mm. In comparison, each non-animal gelling agent capsule shell composition with a water-soluble polymer (whether PVA itself, pullulan or PVA-PEG copolymer) is stronger, with a strength greater than 5 kg and more elastic, with an elasticity greater than 8 mm.
[0110] Example 3 - Soft Gel Shell Composition - Dissolution Data
[0111] Soft gel shell compositions prepared using different concentrations and types of water-soluble polymers were cut into 1" x 1" squares and evaluated for solubility in 0.1N HCl at 37°C in 0.1N HCl and deionized water using USP Apparatus II at a paddle speed of 75 RPM. Table 4 shows the solubility data (also referred to as dissolution data) for shell compositions prepared using various water-soluble polymers.
[0112] The types and concentrations of carrageenan, plasticizers, and buffers used in the samples of Table 4 below were the same as described in Table 2 for Formulations F-2 to F-6.
[0113] Table 4 - Dissolution of dried soft gel shell compositions in 0.1 N HCl medium at 37°C
[0114]
[0115] While not to be construed as limiting, it is believed that the type of water-soluble polymer as well as the weight ratio of carrageenan to a particular water-soluble polymer can affect the dissolution time of the shell composition.
[0116] Example 4 - Soft Gel Capsule Formulation - Dissolution / Disintegration Data
[0117] Placebo soft gel capsules using polyvinyl alcohol and pullulan were manufactured. The soft gel capsules contained 900 mg soybean oil as the filler material. The soft gel shell composition of the encapsulated filler material contained the types and concentrations of carrageenan, plasticizers, and buffers for formulations F-2 to F-6 in Table 2. The types and concentrations of water-soluble polymers in the corresponding soft gel filler materials encapsulating soybean oil are described in Table 5. After drying the capsules, the capsules were subjected to dissolution testing to evaluate the rupture time / solubility of the capsules.
[0118] Dissolution method:
[0119] Equipment: USP Equipment II
[0120] Temperature: 37℃
[0121] Medium: 0.1N HCl
[0122] Paddle speed: 50 and 75 RPM
[0123] Table 5 - Dissolution of Placebo Non-Gelatin Soft Gel Capsules
[0124]
[0125]
[0126] **FASSSGF represents fasting state simulated gastric juice
[0127] As can be seen from Table 5, soft gel capsules with shell compositions comprising water-soluble polymers (PVA or pullulan) exhibit faster dissolution times at 75 RPM at 37° C. in 0.1 N HCl. The dissolution time of the shell composition comprising pullulan in 0.1 N HCl was faster than that of the control group, followed by that of the shell composition comprising PVA. The shell composition comprising pullulan maintained similar dissolution times at 50 RPM at 37° C. in 0.1 N HCl and at 50 RPM at 37° C. in 0.1 N HCl with pepsin.
[0128] Using USP disintegration equipment, disintegration tests were performed on control samples, non-gelatin soft gel capsules without pullulan, and non-gelatin soft gel capsules containing 2% by weight of pullulan. The results are presented in Table 6. The soft gel capsules containing 2% by weight of pullulan broke much faster than the soft gel without pullulan. Adding pullulan made the disintegration faster.
[0129] Table 6 - Disintegration results of non-gelatin soft gel capsules containing pullulan
[0130]
[0131] Example 5 - Comparative Dissolution of Ibuprofen Soft Gel Capsules
[0132] Comparative dissolution testing was performed using non-gelatin soft gel capsules containing 200 mg ibuprofen (made using a standard non-gelatin shell composition and a non-gelatin shell composition containing 2 wt % pullulan according to one embodiment). The soft gel compositions for standard non-gelatin soft gel capsules (CS100A) and for non-gelatin soft gel capsules containing 2 wt % pullulan (according to one embodiment) are summarized in Table 7 below. Figure 1 The results of the study are summarized. Dissolution testing was performed at 37°C in 0.1 N HCl on a USP Apparatus II with a paddle speed of 75 RPM.
[0133] Table 7 - Soft gel composition for ibuprofen soft gel capsules
[0134]
[0135] The results show that the non-gelatin ibuprofen 200 mg soft gel capsule containing 2 wt % pullulan according to one embodiment ruptured earlier at 18 minutes compared to the standard non-gelatin ibuprofen 200 mg soft gel capsule that ruptured at 24 minutes. The similarity factor (F2) was calculated to be 40, which indicates that the two dissolution characteristics are different. The drug release rate of the pullulan soft gel capsule is faster than that of the standard control non-gelatin ibuprofen 200 mg soft gel capsule, which can help achieve a faster start and a shorter T max .
[0136] The term "similar factor (f2)" is a quantitative measure indicating the similarity of the release characteristics of two dosage forms. If the f2 value is not less than about 50 (based on the FDA Guidance to Industry issued in December 2017 on bioequivalence studies of solid oral dosage forms), the release characteristics of the two dosage forms are comparable, similar or bioequivalent.
[0137] The foregoing description sets forth numerous specific details of embodiments such as specific systems, components, methods, etc., in order to provide a better understanding of several embodiments of the present invention. However, it will be apparent to those skilled in the art that at least some embodiments of the present invention may be implemented without these specific details. In other cases, well-known components or methods are not described in detail in order to avoid unnecessary confusion of the present invention. Therefore, the specific details set forth are exemplary. Specific embodiments may differ from these exemplary details and still be encompassed within the scope of the present invention.
[0138] Although the operation of the method herein is described in a particular order, the order of the operation of each method may be changed so that some operations can be performed in reverse order or so that a particular operation can be performed at least partially in parallel with other operations. In another embodiment, the sub-operations of instructions or different operations can be performed in an intermittent and / or alternating manner.
[0139] It should be understood that the above description is intended to be illustrative rather than restrictive. Many other embodiments will be apparent to those skilled in the art after reading and understanding the above description. Therefore, the scope of the present invention should be determined with reference to the appended claims, together with the full range of equivalents authorized by such claims.
Claims
1. A soft gel composition comprising: A shell composition comprising a non-animal source gelling agent and a water-soluble polymer, wherein the shell composition completely dissolves in less than 30 minutes when subjected to dissolution testing at 37°C in 900 ml of 0.1N HCl and deionized water using a USP apparatus II with paddles at 75 RPM, wherein the water-soluble polymer comprises polyvinyl alcohol, pullulan, polylactic acid, polyvinyl alcohol-polyethylene glycol graft copolymer, high molecular weight polyethylene glycol, povidone, a surfactant, or a combination thereof; and The shell composition encapsulates a filler material, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 3:1 to 1:3; The surfactant is sodium lauryl sulfate.
2. The soft gel composition of claim 1, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 2:1 to 1:
2.
3. The soft gel composition of claim 1, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 1:
1.
4. The soft gel composition of any one of claims 1 to 3, wherein the non-animal source gelling agent comprises carrageenan, starch, pregelatinized starch, xanthan gum, agar, pectin, alginate, sugar, high molecular weight polyethylene glycol, sugar-derived alcohol, cellulose derivatives, cellulose polymers, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, microcrystalline cellulose, attapulgite, bentonite, dextrin, alginate, kaolin, lecithin, magnesium aluminum silicate, carbomer, carbopol, silicon dioxide, curdlan, furcellaran, albumin, soy protein, chitosan, or a combination thereof.
5. The soft gel composition of any one of claims 1-3, wherein the shell composition further comprises a plasticizer.
6. The soft gel composition of claim 4, wherein the shell composition further comprises a plasticizer.
7. The soft gel composition of any one of claims 1-3 and 6, wherein the shell composition further comprises a buffer.
8. The soft gel composition of claim 4, wherein the shell composition further comprises a buffer.
9. The soft gel composition of claim 5, wherein the shell composition further comprises a buffer.
10. The soft gel composition of any one of claims 1-3, 6, 8, and 9, wherein the shell composition dissolves in less than 25 minutes.
11. The soft gel composition of claim 10, wherein the shell composition dissolves in less than 20 minutes.
12. The soft gel composition of claim 10, wherein the shell composition dissolves in less than 15 minutes.
13. The soft gel composition of claim 10, wherein the shell composition dissolves in less than 10 minutes.
14. The soft gel composition of claim 10, wherein the shell composition dissolves in less than 5 minutes.
15. The soft gel composition of claim 4, wherein the shell composition dissolves in less than 25 minutes.
16. The soft gel composition of claim 4, wherein the shell composition dissolves in less than 20 minutes.
17. The soft gel composition of claim 4, wherein the shell composition dissolves in less than 15 minutes.
18. The soft gel composition of claim 4, wherein the shell composition dissolves in less than 10 minutes.
19. The soft gel composition of claim 4, wherein the shell composition dissolves in less than 5 minutes.
20. The soft gel composition of claim 5, wherein the shell composition dissolves in less than 25 minutes.
21. The soft gel composition of claim 5, wherein the shell composition dissolves in less than 20 minutes.
22. The soft gel composition of claim 5, wherein the shell composition dissolves in less than 15 minutes.
23. The soft gel composition of claim 5, wherein the shell composition dissolves in less than 10 minutes.
24. The soft gel composition of claim 5, wherein the shell composition dissolves in less than 5 minutes.
25. The soft gel composition of claim 7, wherein the shell composition dissolves in less than 25 minutes.
26. The soft gel composition of claim 7, wherein the shell composition dissolves in less than 20 minutes.
27. The soft gel composition of claim 7, wherein the shell composition dissolves in less than 15 minutes.
28. The soft gel composition of claim 7, wherein the shell composition dissolves in less than 10 minutes.
29. The soft gel composition of claim 7, wherein the shell composition dissolves in less than 5 minutes.
30. The soft gel composition of any one of claims 1-3, 6, 8, 9, and 11-29, wherein the non-animal based gelling agent comprises carrageenan and starch.
31. The soft gel composition of claim 4, wherein the non-animal based gelling agent comprises carrageenan and starch.
32. The soft gel composition of claim 5, wherein the non-animal based gelling agent comprises carrageenan and starch.
33. The soft gel composition of claim 7, wherein the non-animal based gelling agent comprises carrageenan and starch.
34. The soft gel composition of claim 10, wherein the non-animal based gelling agent comprises carrageenan and starch.
35. The soft gel composition of any one of claims 1-3, 6, 8, 9, 11-29, and 31-34, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
10.
36. The soft gel composition of claim 35, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
8.
37. The soft gel composition of claim 35, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
5.
38. The soft gel composition of claim 35, wherein the weight ratio of carrageenan to starch in the shell composition is 1:2.5 to 1:4.
5.
39. The soft gel composition of claim 4, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
10.
40. The soft gel composition of claim 4, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
8.
41. The soft gel composition of claim 4, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
5.
42. The soft gel composition of claim 4, wherein the weight ratio of carrageenan to starch in the shell composition is 1:2.5 to 1:4.
5.
43. The soft gel composition of claim 5, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
10.
44. The soft gel composition of claim 5, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
8.
45. The soft gel composition of claim 5, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
5.
46. The soft gel composition of claim 5, wherein the weight ratio of carrageenan to starch in the shell composition is 1:2.5 to 1:4.
5.
47. The soft gel composition of claim 7, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
10.
48. The soft gel composition of claim 7, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
8.
49. The soft gel composition of claim 7, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
5.
50. The soft gel composition of claim 7, wherein the weight ratio of carrageenan to starch in the shell composition is 1:2.5 to 1:4.
5.
51. The soft gel composition of claim 10, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
10.
52. The soft gel composition of claim 10, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
8.
53. The soft gel composition of claim 10, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
5.
54. The soft gel composition of claim 10, wherein the weight ratio of carrageenan to starch in the shell composition is 1:2.5 to 1:4.
5.
55. The soft gel composition of claim 30, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
10.
56. The soft gel composition of claim 30, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
8.
57. The soft gel composition of claim 30, wherein the weight ratio of carrageenan to starch in the shell composition is 1:1 to 1:
5.
58. The soft gel composition of claim 30, wherein the weight ratio of carrageenan to starch in the shell composition is 1:2.5 to 1:4.
5.
59. The soft gel composition of claim 35, wherein the carrageenan comprises iota carrageenan, kappa carrageenan, lambda carrageenan, or a combination thereof.
60. The soft gel composition of any one of claims 36-58, wherein the carrageenan comprises iota carrageenan, kappa carrageenan, lambda carrageenan, or a combination thereof.
61. The soft gel composition of claim 35, wherein the starch comprises natural starch, modified starch, potato starch, corn starch, tapioca starch, pea starch, hydroxypropylated starch, hydroxyalkylated starch, acid-treated starch, dextrin, and combinations thereof.
62. The soft gel composition of any one of claims 36-59, wherein the starch comprises natural starch, modified starch, potato starch, corn starch, tapioca starch, pea starch, hydroxypropylated starch, hydroxyalkylated starch, acid-treated starch, dextrin, and combinations thereof.
63. The soft gel composition of claim 60, wherein the starch comprises natural starch, modified starch, potato starch, corn starch, tapioca starch, pea starch, hydroxypropylated starch, hydroxyalkylated starch, acid-treated starch, dextrin, and combinations thereof.
64. The soft gel composition of any one of claims 1-3, 6, 8, 9, 11-29, 31-34, 36-59, 61 and 63, wherein the amount of the non-animal gelling agent is 2 wt % to 40 wt %, based on the total weight of the soft gel capsule shell composition.
65. The soft gel composition of claim 4, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
66. The soft gel composition of claim 5, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
67. The soft gel composition of claim 7, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
68. The soft gel composition of claim 10, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
69. The soft gel composition of claim 30, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt% based on the total weight of the soft gel capsule shell composition.
70. The soft gel composition of claim 35, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
71. The soft gel composition of claim 60, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
72. The soft gel composition of claim 62, wherein the amount of the non-animal gelling agent is 2 wt% to 40 wt%, based on the total weight of the soft gel capsule shell composition.
73. The soft gel composition of any one of claims 1-3, 6, 8, 9, 11-29, 31-34, 36-59, 61, 63, and 65-72, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
74. The soft gel composition of claim 73 comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
75. The soft gel composition of claim 73, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
76. The soft gel composition of claim 4 comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
77. The soft gel composition of claim 4 comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
78. The soft gel composition of claim 4 comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
79. The soft gel composition of claim 5, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
80. The soft gel composition of claim 5, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
81. The soft gel composition of claim 5 comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
82. The soft gel composition of claim 7 comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
83. The soft gel composition of claim 7, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
84. The soft gel composition of claim 7 comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
85. The soft gel composition of claim 10, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
86. The soft gel composition of claim 10, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
87. The soft gel composition of claim 10, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
88. The soft gel composition of claim 30, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
89. The soft gel composition of claim 30, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
90. The soft gel composition of claim 30, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
91. The soft gel composition of claim 35, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
92. The soft gel composition of claim 35, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
93. The soft gel composition of claim 35, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
94. The soft gel composition of claim 60, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
95. The soft gel composition of claim 60, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
96. The soft gel composition of claim 60, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
97. The soft gel composition of claim 62, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
98. The soft gel composition of claim 62, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
99. The soft gel composition of claim 62, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
100. The soft gel composition of claim 64, comprising less than 10 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
101. The soft gel composition of claim 64, comprising less than 5 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
102. The soft gel composition of claim 64, comprising less than 1 weight percent of an animal-derived gelling agent, based on the total weight of the soft gel capsule shell composition.
103. The soft gel composition of any one of claims 1-3, 6, 8, 9, 11-29, 31-34, 36-59, 61, 63, 65-72, and 74-102, wherein the shell composition does not contain an animal-derived gelling agent.
104. The soft gel composition of claim 4, wherein the shell composition does not contain an animal-derived gelling agent.
105. The soft gel composition of claim 5, wherein the shell composition does not contain an animal-derived gelling agent.
106. The soft gel composition of claim 7, wherein the shell composition does not contain an animal-derived gelling agent.
107. The soft gel composition of claim 10, wherein the shell composition does not contain an animal-derived gelling agent.
108. The soft gel composition of claim 30, wherein the shell composition does not contain an animal-derived gelling agent.
109. The soft gel composition of claim 35, wherein the shell composition does not contain an animal-derived gelling agent.
110. The soft gel composition of claim 60, wherein the shell composition does not contain an animal-derived gelling agent.
111. The soft gel composition of claim 62, wherein the shell composition does not contain an animal-derived gelling agent.
112. The soft gel composition of claim 64, wherein the shell composition does not contain an animal-derived gelling agent.
113. The soft gel composition of claim 73, wherein the shell composition does not contain an animal-derived gelling agent.
114. The soft gel composition of claim 5, wherein the plasticizer comprises glycerin, sorbitol, sorbitol and sorbitan solution, triacetin, sodium lauryl sulfate, or a combination thereof.
115. The soft gel composition of claim 6, wherein the plasticizer comprises glycerin, sorbitol, sorbitol and sorbitan solution, triacetin, sodium lauryl sulfate, or a combination thereof.
116. The soft gel composition of claim 4, comprising the high molecular weight polyethylene glycol, wherein the high molecular weight polyethylene glycol has a number average molecular weight range of 600 Da - 2,000,000 Da or a combination of polyethylene glycols with different number average molecular weights within the range of 600 Da - 2,000,000 Da.
117. The soft gel composition of claim 5, wherein the amount of the plasticizer in the soft gel capsule shell composition is 0.5 wt% to 40 wt% based on the total weight of the soft gel capsule shell composition.
118. The soft gel composition of claim 6, wherein the amount of the plasticizer in the soft gel capsule shell composition is 0.5 wt% to 40 wt% based on the total weight of the soft gel capsule shell composition.
119. The soft gel composition of claim 7, wherein the amount of the buffer in the soft gel capsule shell composition is 0.1 wt% to 5 wt%, based on the total weight of the soft gel capsule shell composition.
120. The soft gel composition of any one of claims 8-9, wherein the amount of the buffer in the soft gel capsule shell composition is 0.1 wt% to 5 wt%, based on the total weight of the soft gel capsule shell composition.
121. The soft gel composition of claim 7, wherein the buffer is selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium bicarbonate, sodium citrate, disodium phosphate, calcium phosphate, dicalcium hydrogen phosphate, tricalcium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and combinations thereof.
122. The soft gel composition of any one of claims 8-9, wherein the buffer is selected from disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium bicarbonate, sodium citrate, disodium phosphate, calcium phosphate, dicalcium hydrogen phosphate, tricalcium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and combinations thereof.
123. A soft gel composition comprising A fill material comprising an active agent or a cosmetic agent, wherein the fill material is encapsulated by a shell composition, and wherein the shell composition comprises a non-animal gelling agent and a water-soluble polymer, wherein the shell composition completely dissolves in less than 30 minutes when subjected to a dissolution test at 37°C in 900 ml of 0.1N HCl and deionized water using a USP apparatus II with paddles at 75 RPM, wherein the water-soluble polymer comprises polyvinyl alcohol, pullulan gum, polylactic acid, polyvinyl alcohol-polyethylene glycol graft copolymer, high molecular weight polyethylene glycol, povidone, a surfactant or a combination thereof; wherein the surfactant is sodium lauryl sulfate, and wherein the weight ratio of the water-soluble polymer to the non-animal gelling agent is 3:1 to 1:
3.
124. The soft gel composition of claim 123, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 2:1 to 1:
2.
125. The soft gel composition of claim 123, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 1:
1.
126. A soft gel composition comprising a fill material encapsulated by a shell composition, wherein the shell composition comprises: Non-animal-derived gelling agents including carrageenan, starch, or a combination thereof; and A water-soluble polymer comprising polyvinyl alcohol, pullulan, polylactic acid, polyvinyl alcohol-polyethylene glycol graft copolymer, high molecular weight polyethylene glycol, povidone, a surfactant or a combination thereof, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 3:1 to 1:3; The surfactant is sodium lauryl sulfate.
127. The soft gel composition of claim 126, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 2:1 to 1:
2.
128. The soft gel composition of claim 126, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 1:
1.
129. The soft gel composition of any one of claims 123-128, wherein the filler material comprises a hydrophilic material, a lipophilic material, an amphiphilic material, or a combination thereof.
130. The soft gel composition of any one of claims 123-128, wherein the shell composition comprises a surfactant, wherein the surfactant is sodium lauryl sulfate.
131. The soft gel composition of claim 129, wherein the shell composition comprises a surfactant, wherein the surfactant is sodium lauryl sulfate.
132. The soft gel composition of any one of claims 123-128 and 131, wherein the fill material is a solution, a suspension, a semisolid or a solid.
133. The soft gel composition of claim 129, wherein the fill material is a solution, a suspension, a semisolid, or a solid.
134. The soft gel composition of claim 130, wherein the fill material is a solution, a suspension, a semisolid, or a solid.
135. The soft gel composition of any one of claims 126-128, 131, and 133-134, wherein the filler material comprises an active agent or a cosmetic agent.
136. The soft gel composition of claim 129, wherein the filler material comprises an active agent or a cosmetic agent.
137. The soft gel composition of claim 130, wherein the filler material comprises an active agent or a cosmetic agent.
138. The soft gel composition of claim 132, wherein the filler material comprises an active agent or a cosmetic agent.
139. A method for preparing a soft gel composition, comprising: combining a non-animal gelling agent, a water-soluble polymer, and optionally at least one of a buffer, a plasticizer, or water to form a combination; wherein the water-soluble polymer comprises polyvinyl alcohol, pullulan, polylactic acid, polyvinyl alcohol-polyethylene glycol graft copolymer, high molecular weight polyethylene glycol, povidone, a surfactant or a combination thereof; wherein the surfactant is sodium lauryl sulfate; and encapsulating a fill material in a shell composition comprising the combination, The weight ratio of the water-soluble polymer to the non-animal source gelling agent is 3:1 to 1:
3.
140. The method of claim 139, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 2:1 to 1:
2.
141. The method of claim 139, wherein the weight ratio of the water-soluble polymer to the non-animal source gelling agent is 1:
1.
142. The method of any one of claims 139-141, wherein the combination comprises: mixing the plasticizer with water to form a plasticizer solution; and The water soluble polymer, the non-animal gelling agent, and the buffer are mixed with the plasticizer solution to form the combination.
143. The method of any one of claims 139-141, wherein the combination comprises: mixing a plasticizer, a non-animal gelling agent, and water to form a plasticizer solution; The water soluble polymer and the buffer are mixed with the plasticizer solution to form the combination.
144. The method of any one of claims 139-141, further comprising heating the combination to form a melt.
145. The method of claim 142, further comprising heating the combination to form a melt.
146. The method of claim 144, wherein the melt is homogeneous.
147. The method of claim 145, wherein the melt is homogeneous.
148. The method of claim 144, further comprising extruding the melt to form a ribbon.
149. The method of claims 145-147, further comprising extruding the melt to form a ribbon.
150. The method of claim 148, wherein the ribbon has a thickness ranging from 0.001 inches to 0.050 inches.
151. The method of claim 149, wherein the ribbon has a thickness ranging from 0.001 inches to 0.050 inches.
152. Use of the soft gel composition of any one of claims 1-138 or the soft gel composition prepared by the method of any one of claims 139-151 in preparing a medicament for treating a disease.
